Particle.news
Download on the App Store
4 ARTICLES
·
7h ago

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Novo frames the MASP-3 blocker as a differentiated complement therapy, with global Phase 3 testing in PNH planned after closing.

A view shows a Novo Nordisk sign outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. REUTERS/Tom Little/File Photo
Image
Image

Overview

  • Novo obtains exclusive global rights to develop and commercialize zaltenibart for rare blood and kidney disorders.
  • Deal terms include $340 million in upfront and near-term milestone payments, with up to $2.1 billion in total potential payouts plus sales royalties.
  • The transaction is expected to close in the fourth quarter of 2025, after which Novo plans to launch a global Phase 3 program in paroxysmal nocturnal hemoglobinuria and to evaluate other indications.
  • Company statements report the MASP-3 inhibitor was safe and well tolerated in testing and may offer advantages over other alternative-pathway therapies.
  • Omeros retains certain preclinical MASP-3 rights, is seeking this-quarter approval of narsoplimab for transplant-associated thrombotic microangiopathy, and saw its shares nearly triple on the news.